Aliso Viejo drug maker Valeant Pharmaceuticals International licensed a drug to treat lost muscle tone for sale in Canada from Palo Alto-based Jazz Pharmaceuticals Inc., the latest in a string of deals for Valeant.
The deal calls for Valeant to make an undisclosed upfront payment to Jazz and future payments based on Canadian sales of Xyrem. Valeant said in a release that it would launch and distribute Xyrem in Canada in mid-2007 with its sales force.
Valeant’s Jazz deal was preceded by antitrust approval on Thursday for the licensing of a hepatitis B drug for $19.2 million and future payments from Schering-Plough Co.
Valeant plans to work with San Diego-based Metabasis Therapeutics Inc. on the
development of pradefovir.
The drug maker’s been busy on the deal front. Last month, Valeant sold three of its research and development programs to San Diego-based Ardea Biosciences Inc., which also leased more than 62,000 square feet of space to at Valeant’s former corporate offices on Hyland Avenue in Costa Mesa.
